Wyeth

Temple University

American Home Products Corporation

University of Rochester

University of Nebraska

Shifa Biomedical Corporation

Cortendo Ab (publ)

Wayne Everett Childers

Michael G Kelly

Magid A Abou-Gharbia

Yvette L Palmer

Sharon J Rosenzweig-Lipson

George C Morton

Paul M Dunman

Edward J Podlesny

Gan Zhang

Benjamin E Blass

Salim Merali

Lee Erwin Schechter

Patrick D Olson

Carlos A Barrero

Rogelio Martinez

Boyd Lynn Harrison

John P Yardley

Annmarie Louise Sabb

Horace Fletcher, Iii

Lisa Marie Havran

Jean-Pierre J Issa

Hanghang Zhang

Mercy Ramanjulu

Marlene A Jacobson

James Jacob Bicksler

Albert Jean Robichaud

Shaker Ahmed Mousa

Nabil A Elshourbagy

Donna Mary Huryn

Paul Jeffrey Dollings

Robert L Vogel

Magda Asselin

Alexander Greenfield

Arlene J Dietrich

George Theodore Grosu

Sherin Salaheldin Abdel-Meguid

Harold V Meyers

Byron Abel Bravo

Zhongqi Shen

Oscar Mauricio Perez Leal

Callain Younghee Kim

Stacey J Sukoff Rizzo

Chae-Koo Dan Chong

Victor Ghidu

Vasilios Marathias

Jerome C Wu

Edward G Melenski

Pravin Iyer

Joshodeep Boruwa

Reinhartd B Baudy

Rong Fan

Mario Cesar Rico

Magid Abu-Gharbia

Dan Chaekoo Chong

(S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis.

(S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis

Pharmaceutical compositions of the invention comprise functionalized N,N-dialkylamino phenyl ethers derivatives having a disease-modifying action in the treatment of diseases associated with lysosomal storage dysfunction that include Gaucher's disease, and any disease or condition involving lysosomal storage dysfunction.

Functionalized N,N-dialkylamino phenyl ethers and their method of use

The present invention includes novel aminothiazole compounds of formula (I), which are useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of formula (I)

Aminothiazole compounds and methods using same

Compounds of Formula (I), and pharmaceutically effective salts thereof; wherein R-R, m, n, o, p, q and r are as defined herein, are provided for treatment of for increasing insulin sensitivity, reducing insulin resistance, preventing insulin resistance and treating insulin resistance disorders.

Compositions and methods for treatment of insulin resistance

Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in its etiology.

Beta lactams as modulators of glutamate uptake and methods for use thereof

Compounds of Formula (I), and pharmaceutically effective salts thereof; wherein R-R, m, n, o, p, q and r are as defined herein, are provided for treatment of for increasing insulin sensitivity, reducing insulin resistance, preventing insulin resistance and treating insulin resistance disorders. 

The present invention includes novel aminothiazole compounds of formula (I) useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.

Disclosed are compounds of the class of 2-phenylacetamides that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), and methods of using these modulators to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.

Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

Synergistic pharmaceutical compositions including an RNase P inhibitor and a tRNA synthetase inhibitor are provided, as well as methods for their use in treating infections. Also provided herein are methods of using the compositions to inhibit a bacterial tRNA synthetase in a cell and to decolonize bacteria on a surface.

Synergistic compositions for treating microbial infections

Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in it etiology.

Embodiments of the present invention relate to novel cytochrome P450 inhibitors and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the production of cortisol that include metabolic syndrome, obesity, headache, depression, hypertension, diabetes mellitus, Cushing's Syndrome, pseudo-Cushing syndrome, cognitive impairment, dementia, heart failure, renal failure, psoriasis, glaucoma, cardiovascular disease, cancer, stroke or incidentalomas.

Cytochrome P450 inhibitors and their method of use

Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. Also described herein are methods of identifying compounds for treating or preventing a microbial infection.

Small molecule RNase inhibitors and methods of use

The invention provides an isolated nucleic acid having a sequence encoding a spermidine/spermine acetyltransferase ('SSAT'), wherein translation of an mRNA comprising the encoded SSAT has increased basal translation and increased stimulated translation, compared to a wild-type mRNA encoding SSAT. Methods of use for the nucleic acid are also provided. Methods and compositions are also provided for reducing ischemia-reperfusion injury in organs or tissue for transplantation.

SSAT mRNA translation repression and activation

Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease.

Growing community of inventors

New Hope, PA, United States of America

Wayne Everett Childers